Summary: Heart failure is a significant civilization problem. Worldwide, 64.3 million people suffer from heart failure. Heart failure significantly worsens the quality of life and increases the risk of premature death. A common disorder in patients with heart failure is abnormal heart rate. Too fast heart rate worsens the prognosis of patients with heart failure, and therefore requires appropriate treatment. The use of beta-blockers does not fully protect patients against the negative effects of increased heart rate on the prognosis. Ivabradine is a relatively new drug that lowers the heart rate while devoid of most of the side effects of beta-blockers. It has been shown that the addition of ivabradine to the standard treatment of patients with HF allows for greater control of the heart rate, which translates into a signifi-cant clinical improvement in these patients. Moreover, it has been shown that ivabradine prolongs the life of patients with HF. Attention is drawn to the need to use the combination of β-blockers with ivabradine as early as possible - in order to achieve a heart rate < 60 quickly and effectively, without the need to escalate such a large dose of β-blockade.